RxDoctor Payments Data

John Gallo, DO

Internal Medicine · Pittsburg, CANPI 1558446229

Payments from drug & device makers

$1,191in general payments, 2019–2025

Across 12 payments — averaging $99.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$810
  • Boehringer Ingelheim$225
  • AstraZeneca$125
  • Tactile Systems Technology Inc$16
  • Lilly USA, LLC$15

What the payments were for

  • Food & beverage$1,191100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,191 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$199,213
Medicare patients
517
Services billed
1,888

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban144$132,405
OzempicSemaglutide64$101,780
JardianceEmpagliflozin44$62,515
XareltoRivaroxaban45$53,876
JanuviaSitagliptin Phosphate39$53,536
BiktarvyBictegrav/Emtricit/Tenofov Ala12$46,008
RybelsusSemaglutide16$34,047
FarxigaDapagliflozin Propanediol21$29,249
MounjaroTirzepatide24$26,909
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$24,221
MyrbetriqMirabegron17$22,532
TrulicityDulaglutide11$11,773
SymbicortBudesonide/Formoterol Fumarate28$10,087
Albuterol Sulfate HfaAlbuterol Sulfate198$6,666
Atorvastatin Calcium614$5,497

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$225$62,51544 claims
AstraZenecaFarxiga, Symbicort$125$39,33649 claims
Lilly USA, LLCMounjaro, Trulicity$15$38,68235 claims
GSKTrelegy Ellipta, Arnuity Ellipta$810$28,50441 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Pittsburg

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →